Prophylaxis study using ivermectin and carrageenan showing 0 of 131 cases from treated healthcare workers, compared to 11 of 98 control.
The effect is likely to be primarily due to ivermectin - the author has later reported that carrageenan is not necessary
1.
See
2 for discussion of issues with this trial.
Targeted administration to the respiratory tract provides treatment directly
to the typical source of initial SARS-CoV-2 infection and replication, and
allows for rapid onset of action, higher local drug concentration, and reduced systemic side effects.
This study is excluded in meta
analysis:
combined treatment may significantly contribute to efficacy, concern about potential data issues.
|
risk of case, 96.3% lower, RR 0.04, p < 0.001, treatment 0 of 131 (0.0%), control 11 of 98 (11.2%), NNT 8.9, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
|
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Carvallo et al., 19 Oct 2020, prospective, Argentina, preprint, 1 author, this trial uses multiple treatments in the treatment arm (combined with iota-carrageenan) - results of individual treatments may vary, trial
NCT04425850 (history).
